The Globe and Mail reports in its Monday edition that on Friday, management of Vancouver-based cancer therapy developer Zymeworks rang the bell on the Toronto Stock Exchange, five weeks after its stock debuted in a $59-million (U.S.) initial public offering. The Globe's Sean Silcoff writes that it was by far the largest biotech IPO on a Canadian exchange in a decade and came on the heels of one of the largest stock offerings ever by a Canadian biotech firm, after dual-listed lupus-drug developer Aurinia Pharmaceuticals raised $150.5-million in March. Those deals are the latest in a surge of financing for Canadian pharmaceutical developers. Life-sciences firms raised $1.1-billion in venture capital last year, double 2015 levels. Next up is a likely initial public offering from Montreal's Clementia Pharmaceuticals Inc., which recently announced positive clinical-trial results for its treatment for a rare genetic condition. The company, led by neurosurgeon Clarissa Desjardins, is hoping to raise $100-million in an IPO as early as this summer. "You're starting to see a whole generation of Canadian companies that are very different than what we've seen" in the past, said Peter van der Velden at Lumira Capital.